(Total Views: 707)
Posted On: 05/18/2022 10:31:08 PM
Post# of 148902
On the topic of CEO, we need to give Tanya Durkee Urbach the time necessary to do her job. She will find the right individual.
About 6 weeks ago, I described what I felt CytoDyn needed in terms of new CEO and I put the following out on Reddit:
Needless to say, CytoDyn is currently searching for a CEO. With the versatility of Leronlimab, CytoDyn believes that their path forward is to develop multiple Pharmaceutical partnerships made with companies in varied fields, (ranging from HIV, to Oncology to Liver Disease & beyond), to use Leronlimab in combination therapy with their approved drug to augment its effectiveness for their specific indications.
CytoDyn is currently searching for a CEO who has serious connections in the Pharmaceutical Industry. The CEO needs to have a special drive to help people deal with awful diseases such as HIV and Cancer. He would have a deep ambition for, and personal goals of helping humanity with cures for patients with cancer, HIV, and also for treating the numerous maladies which Leronlimab successfully combats by blocking CCR5. The CEO would learn and understand the mechanism of action of Leronlimab and clearly understand the complexity, the versatility, flexibility and extensive usefulness & broadness of the applications which Leronlimab easily addresses.
As such, this CEO would help humanity by delivering Leronlimab to the people through his own, previously established, network of connections. He would bring CytoDyn together with a diverse group of Big Pharmaceutical companies into partnerships to treat a variety of their indications. Through his direction, and using Leronlimab’s versatility, CytoDyn would enter into partnerships with Big Pharmaceuticals on indications that those Big Pharmaceuticals specialize in, helping them to achieve their goals while CytoDyn achieves theirs.
The CEO would be versed in business and medicine. He would understand patent law. He would have published papers. A passion of his is to help people fight disease through the use of medicine and health care. He would do this by bringing multiple companies together, (even those who may be rivals with one another), into a sort of “coalition” through CytoDyn with the augmentation of Leronlimab to the current treatment regimen.
Nader Poorhassan had set the stage, but that stage is now closing, marked by his termination. The new CytoDyn marked by partnerships begins with the incoming CEO. CytoDyn is currently in transition.
About 6 weeks ago, I described what I felt CytoDyn needed in terms of new CEO and I put the following out on Reddit:
Needless to say, CytoDyn is currently searching for a CEO. With the versatility of Leronlimab, CytoDyn believes that their path forward is to develop multiple Pharmaceutical partnerships made with companies in varied fields, (ranging from HIV, to Oncology to Liver Disease & beyond), to use Leronlimab in combination therapy with their approved drug to augment its effectiveness for their specific indications.
CytoDyn is currently searching for a CEO who has serious connections in the Pharmaceutical Industry. The CEO needs to have a special drive to help people deal with awful diseases such as HIV and Cancer. He would have a deep ambition for, and personal goals of helping humanity with cures for patients with cancer, HIV, and also for treating the numerous maladies which Leronlimab successfully combats by blocking CCR5. The CEO would learn and understand the mechanism of action of Leronlimab and clearly understand the complexity, the versatility, flexibility and extensive usefulness & broadness of the applications which Leronlimab easily addresses.
As such, this CEO would help humanity by delivering Leronlimab to the people through his own, previously established, network of connections. He would bring CytoDyn together with a diverse group of Big Pharmaceutical companies into partnerships to treat a variety of their indications. Through his direction, and using Leronlimab’s versatility, CytoDyn would enter into partnerships with Big Pharmaceuticals on indications that those Big Pharmaceuticals specialize in, helping them to achieve their goals while CytoDyn achieves theirs.
The CEO would be versed in business and medicine. He would understand patent law. He would have published papers. A passion of his is to help people fight disease through the use of medicine and health care. He would do this by bringing multiple companies together, (even those who may be rivals with one another), into a sort of “coalition” through CytoDyn with the augmentation of Leronlimab to the current treatment regimen.
Nader Poorhassan had set the stage, but that stage is now closing, marked by his termination. The new CytoDyn marked by partnerships begins with the incoming CEO. CytoDyn is currently in transition.
(4)
(1)Scroll down for more posts ▼
